Cassady Schiller Wealth Management LLC Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Cassady Schiller Wealth Management LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 28.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,784 shares of the biopharmaceutical company’s stock after selling 1,133 shares during the period. Cassady Schiller Wealth Management LLC’s holdings in Pfizer were worth $74,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Gladius Capital Management LP lifted its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC purchased a new stake in Pfizer during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on PFE. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.5 %

NYSE:PFE opened at $25.74 on Monday. The firm has a market capitalization of $145.85 billion, a P/E ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company’s fifty day moving average price is $26.24 and its 200-day moving average price is $27.12. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.